Research programme: erythropoietin/albumin - Teva

Drug Profile

Research programme: erythropoietin/albumin - Teva

Alternative Names: Albumin/erythropoietin; Albupoietin; EPO/albumin; Long-acting EPO - Teva; Long-acting erythropoietin

Latest Information Update: 12 Aug 2011

Price : $50

At a glance

  • Originator CoGenesys
  • Developer Teva Pharmaceutical Industries
  • Class Erythropoietins
  • Mechanism of Action Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Anaemia

Most Recent Events

  • 22 Feb 2008 CoGenesys has been acquired and merged into Teva Pharmaceutical Industries
  • 30 Aug 2006 This programme is available for licensing (http://www.cogenesys.com)
  • 12 Jun 2006 CoGenesys has acquired this programme from Human Genome Sciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top